Systemic Scleroderma Treatment Market to Surpass US$ 2,027.4 Million by 2028 - Coherent Market Insights

Global Systemic Scleroderma Treatment Market, by Drug Class (Immunosuppressors, Calcium Channel Blockers, Proton Pump Inhibitors, Phosphodiesterase 5 Inhibitors, Endothelin Receptor Antagonists, Prostacyclin Analogues, and Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)), by Disease Type (Limited Systemic Sclerosis, Diffused Systemic Sclerosis, and Systemic Sclerosis Sine Scleroderma), by Route of Administration (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),  and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$  1,520.1  million in 2021 and is expected to exhibit a CAGR of 4.2% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Key players operating in the market are focusing on receiving product approvals from regulatory authorities and this is expected to drive the global systemic scleroderma treatment market growth over the forecast period.

For instance, in January 2021, Timber Pharmaceuticals LLC, a U.S. based pharmaceutical company received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its drug TMB-003 (sitaxsentan). TMB-003 is a highly selective endothelin receptor antagonist which can be used for treatment of systemic scleroderma.

Global Systemic Scleroderma Treatment Market – Impact of Coronavirus (Covid-19) Pandemic

COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 211 million cases and 4.4 million deaths due to Coronavirus (COVID-19) were reported up till August 22, 2021, across the globe.

The COVID-19 pandemic has affected several markets across the globe and is also expected to hamper the demand and supply in global systemic scleroderma treatment market. The COVID-19 pandemic has affected the demand and supply of global systemic scleroderma treatment market in three main ways; by directly affecting the production and demand of systemic scleroderma treatments; by creating disruptions in distribution channels; and by its financial impact on firms and markets. Supply chain and manufacturing activities of pharmaceutical companies in India, China, and the U.S. are disrupted due to nationwide lockdowns. Furthermore, the COVID-19 pandemic has negatively impacted the global economy. However, COVID-19 pandemic is expected to have a positive impact on systemic scleroderma treatment market due to its association with systemic scleroderma.

For instance, according to an article published by the Clinical Rheumatology journal in March 2020, it has been observed that people suffering from systemic scleroderma related interstitial lung disease (ILD) in the U.S. are more prone to severe COVID-19 complications and deaths than those without interstitial lung disease.

Browse 33 Market Data Tables and 24 Figures spread through 164 Pages and in-depth TOC on “Systemic Scleroderma Treatment Market”- Global Forecast to 2028, by Drug Class (Immunosuppressors, Calcium Channel Blockers, Proton Pump Inhibitors, Phosphodiesterase 5 Inhibitors, Endothelin Receptor Antagonists, Prostacyclin Analogues, and Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)), by Disease Type (Limited Systemic Sclerosis, Diffused Systemic Sclerosis, and Systemic Sclerosis Sine Scleroderma), by Route of Administration (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the global systemic scleroderma treatment market, click the link below:

https://www.coherentmarketinsights.com/market-insight/systemic-scleroderma-treatment-market-4641

Key players operating in the market are focusing on adoption of inorganic growth strategies such as collaborations and acquisitions, in order to strengthen their position in the market. For instance, in December 2019, Servier Laboratories, a France based pharmaceutical company collaborated with University College London to develop novel therapeutics for treatment of immune inflammatory diseases such as lupus and systemic sclerosis.

Key Takeaways of the Global Systemic Scleroderma Treatment Market:

• The global systemic scleroderma treatment market is expected to exhibit a CAGR of 4.2% over the forecast period, owing presence of strong pipeline products. For instance, in July 2020, Talaris Therapeutics, a U.S. based biotechnology company received the U.S. Food and Drug Administration (FDA) approval for its new cell therapy FCR001 to be used to treat patients suffering from diffuse systemic sclerosis.
• Among drug class, immunosuppressor segment accounted for the largest market share in 2020, owing to market players focusing on obtaining drug approvals. For instance, in March 2021, Genentech, Inc., a U.S. based biotechnology company received the U.S. FDA approval for its drug Actemra (Tocilizumab), an immunosuppressor which can be used against systemic scleroderma.
• Key players operating in the global systemic scleroderma treatment market include Bristol-Myers Squibb Company, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Corbus Pharmaceuticals, Actelion Pharmaceuticals Ltd., Allergan, F. Hoffmann-La Roche Ltd., Biogen, Novartis AG, AstraZeneca, Celgene corporation, Ono pharmaceutical co. Ltd., Teva Pharmaceutical Industries Ltd., Aspen Holdings, Pfizer Inc., Eli Lilly and Company, Bayer AG, Amgen Inc., Sanofi, and Argentis Pharmaceuticals, LLC